Effects of microRNA‑125b on multiple myeloma cell growth in vitro and in vivo

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• Multiple myeloma (MM) is a heterogeneous plasma cell malignancy with a poor prognosis.
• MicroRNA-125b (miR-125b), identified as an oncomiR, shows elevated expression in various cancers.
• Understanding the role of specific microRNAs in MM pathogenesis is crucial for developing novel therapies.

Purpose of the Study:

• To investigate the expression and functional role of miR-125b in multiple myeloma.
• To elucidate the molecular mechanisms by which miR-125b influences MM cell behavior and signaling pathways.
• To evaluate the therapeutic potential of targeting miR-125b in MM.

Main Methods:

• Real-time PCR was used to quantify miR-125b expression in patient plasma samples and controls.
• Cell proliferation, migration, and invasion assays (CCK-8, etc.) assessed the functional impact of miR-125b.
• Dual-Luciferase reporter assays identified PHLPP2 as a direct target of miR-125b.
• Western blotting analyzed the levels of phosphorylated Akt.
• A xenograft mouse model was employed to evaluate tumor growth inhibition by a miR-125b inhibitor.

Main Results:

• miR-125b expression was significantly increased in plasma from MM patients compared to healthy controls.
• Downregulation of miR-125b inhibited MM cell proliferation, migration, and invasion.
• miR-125b directly targets PH domain and leucine rich repeat protein phosphatase 2 (PHLPP2), leading to increased Akt signaling.
• Inhibition of miR-125b in a xenograft mouse model suppressed tumor growth.

Conclusions:

• miR-125b promotes multiple myeloma progression by inhibiting PHLPP2 and activating Akt signaling.
• Inhibition of miR-125b demonstrates therapeutic potential for MM treatment.
• miR-125b represents a promising novel molecular therapeutic target for multiple myeloma.